S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
NASDAQ:NVCR

NovoCure - NVCR Stock Forecast, Price & News

$75.62
+0.74 (+0.99%)
(As of 08/5/2022 08:49 PM ET)
Add
Compare
Today's Range
$72.21
$75.87
50-Day Range
$56.60
$85.00
52-Week Range
$56.39
$156.45
Volume
380,800 shs
Average Volume
668,087 shs
Market Capitalization
$7.92 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$107.57

NovoCure MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
42.3% Upside
$107.57 Price Target
Short Interest
Bearish
7.26% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.15
Upright™ Environmental Score
News Sentiment
-0.30mentions of NovoCure in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$117,078 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.89) to ($1.11) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

871st out of 1,283 stocks

Surgical & Medical Instruments Industry

91st out of 130 stocks

NVCR stock logo

About NovoCure (NASDAQ:NVCR) Stock

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Wall Street Analyst Weigh In

Several analysts have recently commented on NVCR shares. StockNews.com upgraded shares of NovoCure from a "sell" rating to a "hold" rating in a research note on Monday, May 2nd. HC Wainwright assumed coverage on shares of NovoCure in a research report on Monday, May 16th. They set a "buy" rating and a $115.00 target price for the company. Evercore ISI downgraded shares of NovoCure from an "in-line" rating to an "underperform" rating and set a $55.00 price target for the company. in a report on Tuesday, July 5th. Finally, Piper Sandler lowered their price target on shares of NovoCure from $100.00 to $90.00 in a report on Thursday, July 28th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $107.57.

NovoCure Trading Up 1.0 %

NovoCure stock traded up $0.74 during trading on Friday, reaching $75.62. The company had a trading volume of 380,835 shares, compared to its average volume of 485,435. NovoCure has a 12-month low of $56.39 and a 12-month high of $156.45. The stock's 50 day moving average price is $71.82 and its two-hundred day moving average price is $74.68. The firm has a market capitalization of $7.92 billion, a price-to-earnings ratio of -116.34 and a beta of 0.87. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.87 and a current ratio of 8.08.

NovoCure (NASDAQ:NVCR - Get Rating) last released its earnings results on Thursday, July 28th. The medical equipment provider reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.09). NovoCure had a negative net margin of 12.52% and a negative return on equity of 16.04%. The company had revenue of $140.90 million during the quarter, compared to analysts' expectations of $135.13 million. During the same quarter in the previous year, the firm posted ($0.14) earnings per share. NovoCure's revenue for the quarter was up 5.5% compared to the same quarter last year. As a group, equities analysts expect that NovoCure will post -0.89 earnings per share for the current fiscal year.

Insider Activity at NovoCure

In related news, insider Ely Benaim sold 437 shares of the business's stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $69.66, for a total value of $30,441.42. Following the completion of the sale, the insider now directly owns 34,631 shares in the company, valued at $2,412,395.46. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, insider Ely Benaim sold 437 shares of the business's stock in a transaction on Tuesday, August 2nd. The shares were sold at an average price of $69.66, for a total transaction of $30,441.42. Following the transaction, the insider now directly owns 34,631 shares of the company's stock, valued at $2,412,395.46. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman William F. Doyle sold 837 shares of the business's stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $69.66, for a total transaction of $58,305.42. Following the transaction, the chairman now directly owns 551,176 shares in the company, valued at $38,394,920.16. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,681 shares of company stock worth $117,078. 5.07% of the stock is owned by company insiders.

Receive NVCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter.

NVCR Stock News Headlines

5 Top Stocks for August - Nasdaq
NovoCure (NASDAQ:NVCR) Shares Gap Down After Earnings Miss
NovoCure (NASDAQ:NVCR) PT Lowered to $90.00
Novocure (NVCR) Q2 2022 Earnings Call Transcript
Recap: NovoCure Q2 Earnings - Benzinga
See More Headlines
Receive NVCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter.

NVCR Company Calendar

Last Earnings
7/28/2022
Today
8/07/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVCR
Fax
N/A
Employees
1,167
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$107.57
High Stock Price Forecast
$200.00
Low Stock Price Forecast
$55.00
Forecasted Upside/Downside
+42.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-58,350,000.00
Pretax Margin
-11.37%

Debt

Sales & Book Value

Annual Sales
$535.03 million
Book Value
$4.22 per share

Miscellaneous

Free Float
99,429,000
Market Cap
$7.92 billion
Optionable
Optionable
Beta
0.87














NVCR Stock - Frequently Asked Questions

Should I buy or sell NovoCure stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NovoCure stock.
View analyst ratings for NovoCure
or view top-rated stocks.

What is NovoCure's stock price forecast for 2022?

7 equities research analysts have issued 12-month price targets for NovoCure's stock. Their NVCR stock forecasts range from $55.00 to $200.00. On average, they anticipate NovoCure's share price to reach $107.57 in the next year. This suggests a possible upside of 42.3% from the stock's current price.
View analysts' price targets for NovoCure
or view top-rated stocks among Wall Street analysts.

How has NovoCure's stock price performed in 2022?

NovoCure's stock was trading at $75.08 at the start of the year. Since then, NVCR stock has increased by 0.7% and is now trading at $75.62.
View the best growth stocks for 2022 here
.

When is NovoCure's next earnings date?

NovoCure is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our earnings forecast for NovoCure
.

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) posted its earnings results on Thursday, July, 28th. The medical equipment provider reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.09. The medical equipment provider earned $140.90 million during the quarter, compared to analysts' expectations of $135.13 million. NovoCure had a negative trailing twelve-month return on equity of 16.04% and a negative net margin of 12.52%. The firm's revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.14) EPS.

What is Asaf Danziger's approval rating as NovoCure's CEO?

17 employees have rated NovoCure CEO Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among NovoCure's employees.

What other stocks do shareholders of NovoCure own?

What is NovoCure's stock symbol?

NovoCure trades on the NASDAQ under the ticker symbol "NVCR."

Who are NovoCure's major shareholders?

NovoCure's stock is owned by many different retail and institutional investors. Top institutional shareholders include Frontier Capital Management Co. LLC (0.34%), Sumitomo Mitsui Trust Holdings Inc. (0.26%), Wolverine Asset Management LLC (0.00%), TD Asset Management Inc. (0.12%), State Board of Administration of Florida Retirement System (0.12%) and BNP PARIBAS ASSET MANAGEMENT Holding S.A. (0.11%). Company insiders that own NovoCure stock include Asaf Danziger, Ashley Cordova, Charles G Phillips III, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends for NovoCure
.

How do I buy shares of NovoCure?

Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NovoCure's stock price today?

One share of NVCR stock can currently be purchased for approximately $75.62.

How much money does NovoCure make?

NovoCure (NASDAQ:NVCR) has a market capitalization of $7.92 billion and generates $535.03 million in revenue each year. The medical equipment provider earns $-58,350,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.

How many employees does NovoCure have?

NovoCure employs 1,167 workers across the globe.

How can I contact NovoCure?

NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The official website for NovoCure is www.novocure.com. The medical equipment provider can be reached via phone at 441534756700 or via email at investorinfo@novocure.com.

This page (NASDAQ:NVCR) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.